Navigation Links
FDA OKs Impotence Drug Cialis to Treat Enlarged Prostate
Date:10/6/2011

THURSDAY, Oct. 6 (HealthDay News) -- The U.S. Food and Drug Administration announced late Thursday that it had approved using the erectile dysfunction drug Cialis as a treatment for enlarged prostate.

According to the U.S. National Institutes of Health, enlarged prostate -- clinically known as benign prostatic hyperplasia (BPH) -- is a "common part of aging" for men. In fact, the NIH estimates that "more than half of men in their 60s, and as many as 90 percent in their 70s and 80s, have some symptoms of BPH."

The condition often leads to urinary incontinence and can raise the odds for urinary tract infections and even kidney damage.

"BPH can have a big impact on a patient's quality of life," Scott Monroe, director of the division of reproductive and urologic products in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "A large number of older men have symptoms of BPH. Cialis [tadalifil] offers these men another treatment option, particularly those who also have ED, which is also common in older men," he said.

The FDA said its approval was made on the basis of three studies. Two of the studies looked at changes in BPH symptom severity based on the International Prostate Symptom Score. Those trials found that men who took the 5-milligram dose of Cialis one per day experienced an improvement in BPH symptoms vs. men who took a dummy pill.

A third study, which involved men who suffered from both impotence and enlarged prostate, found that the daily 5-milligram dose of Cialis improved symptoms for both conditions.

The FDA warned that Cialis, which is made by Eli Lilly and Co., "should not be used in patients taking nitrates, for example nitroglycerin, because the combination can cause an unsafe decrease in blood pressure." People taking heart medications known as alpha blockers should also avoid Cialis because its use alongside these drugs has not yet been studied and the combination might lower blood pressure.

Other drugs have already received FDA approval for the treatment of BPH. These include Proscar, (finasteride), Avodart (dutasteride), Jalyn (dutasteride plus tamsulosin), and the alpha blockers Hytrin (terazosin), Cardura (doxazosin), Flomax (tamsulosin), Uroxatral (alfuzosin) and Rapaflo (silodosin).

More information

Find out more about BPH at the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

-- HealthDay Staff

SOURCE: Oct. 6, 2011, news release, U.S. Food and Drug Administration


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Test Predicts Risk for Impotence After Prostate Cancer Therapy
2. Impotence Linked to Restless Legs Syndrome
3. Poor Sleep Tied to Incontinence, Impotence
4. Dangers Lurk in Impotence Drugs Sold on Web
5. Experts call for urgent action to tackle strong links between impotence and heart disease
6. Impotence Drugs May Aid Brain Tumor Treatment
7. Dale Browne, M.D., ear, nose, and throat specialist, receives award from National Medical Society
8. John House, MD, ear, nose, and throat specialist, receives award from National Medical Society
9. Specialists More Likely to Spot Deadly Skin Cancer
10. Specialists Often Turn Away Kids With Public Insurance: Report
11. The best way to conquer migraine is to increase government research funding, headache specialists say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA OKs Impotence Drug Cialis to Treat Enlarged Prostate
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: